Enzyme Replacement Therapy with Idursulfase in Patients with Mucopolysaccharidosis Type II: Literature Review

Enzyme Replacement Therapy with Idursulfase in Patients with Mucopolysaccharidosis Type II: Literature Review

Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is X-linked hereditary disease from the group of lysosomal storage disease. Its prevalence is 3–7 cases per 1 million live-born boys. MPS II occurs due to the deficiency of iduronate-2-sulfatase enzyme because of pathological changes in the str...

Full description

Bibliographic Details
Main Authors: Nato D. Vashakmadze, Natalya V. Zhurkova, Olga B. Gordeeva, Elena V. Komarova, Tatyana E. Privalova, Anastasya I. Rykunova, Marina А. Babaykina
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2021-12-01
Series:Вопросы современной педиатрии
Subjects:
мукополисахаридоз
тип ii
синдром хантера
идурсульфаза
ферментозаместительная терапия
выживаемость
Online Access:https://vsp.spr-journal.ru/jour/article/view/2791

Internet

https://vsp.spr-journal.ru/jour/article/view/2791

Similar Items